Sanofi/GSK Next-Generation COVID-19 Vaccine Shows Promise As Booster
Phase III data from two studies of the adjuvanted recombinant vaccine candidate showed increases in neutralizing antibody titers against the original SARS-CoV-2 strain and variants of concern.
You may also be interested in...
Pfizer/BioNTech Bolster Case For Omicron Vaccines
The bivalent vaccine is likely to get regulatory support, along with government contracts, but competitors, notably Moderna, will also step into the ring.
Novavax’s Pending EUA Likely Less Important Than Future Updates
Upcoming booster, adolescent data may be more commercially significant for the vaccine, which would enter a US market with few willing adults still unvaccinated. The tough prospects for one of the first COVID vaccines in development is a lesson in the importance of avoiding regulatory delays.
Coronavirus Update: Moderna’s Omicron Vaccine Study Successful, But Data Draw Skepticism
AstraZeneca also published efficacy data for Evusheld in patients with mild-to-moderate COVID-19, while Pfizer is investing $120m in expanding its Paxlovid manufacturing footprint in Michigan.